Clinical Trial of SP-2577 in Patients With Relapsed or Refractory Ewing Sarcoma

Status: Recruiting
DFCI Protocol ID: 17-575

Phase 1, open-label, non-randomized dose finding study of SP-2577 in patients with refractory or recurrent Ewing sarcoma.

Conducting Institutions:

Children's Hospital Boston, Dana-Farber Cancer Institute

Overall PI:

Steven Dubois MD, Dana Farber Cancer Institute

Site-responsible Investigators:


Dana-Farber Cancer Institute: Childrens Hospital Pediatric Clinical Translation Investigation Program CTIP,

Eligibility Criteria

Inclusion Criteria:

  -  Patients must have a histologic confirmed diagnosis of Ewing sarcoma that is
     refractory or recurrent and must have received at least one prior course of therapy
     for Ewing sarcoma. For the purposes of this study, refractory disease is defined as
     metastatic or unresectable disease that has either progressed or is stable at
     completion of planned therapy.

  -  Patients must have radiographic evidence of disease. Patients must have disease
     evaluable by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Bone only
     disease that has been biopsy-proven is acceptable during dose escalation but not
     expansion phase.

  -  Patients must have had prior camptothecin-based regimen, have a contraindication to
     camptothecin-based regimen, or declined treatment with a camptothecin-based regimen.

  -  Age ≥ 12 years and weight ≥ 40 kg.

  -  Karnofsky ≥70% for over ≥16 years old and Lansky ≥70% for under 16 years old, see
     Appendix A, equivalent to Eastern Cooperative Oncology Group (ECOG) performance status
     grade 0 or 1

  -  Life expectancy of greater than 4 months.

  -  Patients must have normal organ and marrow function

  -  Archival tumor tissue available for translocation analysis or willingness to provide
     tumor biopsy during screening.

  -  Willingness to provide tumor biopsies on and off treatment (Tier 2: Dose expansion
     cohort only). Optional for patients <18 years of age.

  -  Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  -  Patients who have not recovered to grade 1 or baseline from adverse events related to
     prior therapy excluding lymphopenia, alopecia, peripheral neuropathy and ototoxicity,
     which are excluded if ≥ CTCAE grade 3.

  -  Patients who are receiving any other investigational agents.

  -  Prior therapy with LSD1 targeted agents including monoamine oxidases for cancer

  -  Prior systemic anti-cancer treatment (chemotherapy, biologic therapy [ie. small
     molecular inhibitors, monoclonal antibodies]) within 21 days prior to Cycle 1 Day 1.
     For agents that have known adverse events occurring beyond 21 days after
     administration, this period must be extended beyond the time during which adverse
     events are known to occur. The duration of this interval must be discussed with the
     study chair.

  -  Prior therapy with immunotherapy such as a checkpoint inhibitor, cellular therapy or
     vaccine within 42 days prior to Cycle 1 Day 1

  -  Prior small port palliative radiotherapy within 14 days or 42 days from definitive
     local control radiation (any dose greater than 50Gy).

  -  Prior therapy with long acting myeloid growth factor within 14 days or 7 days from a
     short acting myeloid growth factor.

  -  Evidence of graft versus host disease or prior allo- or auto-bone marrow transplant
     (BMT) or stem cell infusion within 84 days from Cycle 1 Day 1 or receiving
     immunosuppression following a stem cell procedure.

  -  Participation in a prior investigational study within 30 days prior to Cycle 1 Day 1
     or within 5-half-lives of the investigational product, whichever is longer.

  -  Patients with progressive or symptomatic brain metastases. Patients with brain
     metastases may be included in this trial as long as the brain metastases have received
     definitive treatment and are stable (i.e., no evidence of progression). The brain
     metastases must be stable for a minimum of 6 weeks.

  -  Patients currently receiving any of the following substances and cannot be
     discontinued 14 days prior to Cycle 1 Day 1:

       -  Moderate or strong inhibitors or inducers of major CYP isoenzymes, including
  grapefruit, grapefruit hybrids, pomelos, star-fruit, and Seville oranges

       -  Moderate or strong inhibitors or inducers of major drug transporters

       -  Substrates of CYP3A4/5 with a narrow therapeutic index

  -  Uncontrolled concurrent illness including, but not limited to:

       -  ongoing or active infection

       -  transfusion dependent thrombocytopenia or anemia

       -  psychiatric illness/social situations that would limit compliance with study

  -  Clinically significant, uncontrolled heart disease and/or cardiac repolarization
     abnormality, including any of the following:

       -  symptomatic congestive heart failure

       -  Left Ventricular Ejection Fraction (LVEF) ≤ 50%

       -  unstable angina pectoris or cardiac arrhythmia

       -  baseline QTc ≥ 450 milliseconds

       -  Long QT syndrome or family history of idiopathic sudden death or congenital long
  QT syndrome

  -  Any major surgery within 21 days prior to Cycle 1 Day 1.

  -  Pregnant and breastfeeding women are excluded from this study. The effects of SP-2577
     on the developing human fetus have the potential for teratogenic or abortifacient
     effects. There is an unknown but potential risk for adverse events in nursing infants
     secondary to treatment of the mother with SP-2577.

  -  Women of child-bearing potential and men must agree to use adequate contraception
     (hormonal or barrier method of birth control; abstinence) prior to study entry and for
     the duration of study participation. Should a woman become pregnant or suspect she is
     pregnant while she or her partner is participating in this study, she should inform
     her treating physician immediately. Men treated or enrolled on this protocol must also
     agree to use adequate contraception prior to the study, for the duration of study
     participation, and 4 months after completion of SP-2577 administration.

  -  HIV-positive patients on combination antiretroviral therapy are ineligible because of
     the potential for pharmacokinetic interactions with SP-2577. In addition, these
     patients are at increased risk of lethal infections when treated with
     marrow-suppressive therapy.

Know Your Options

Not sure which clinical trials might be right for your child? Email our clinical trials team at
We can help you navigate your options.

Get Clinical Trial Updates


Stay informed about Dana-Farber/Boston Children's research efforts, including information on new and current clinical trials. Sign up to receive our email newsletter Advances in Pediatric Hematology/Oncology.